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Abstract. 
The thyroid is an unusual site to find cancer metastasis. When it does occur, such cancer 
spread is often manifested in multiple metastases and generally suggests a poor prognosis. We 
presented here a 49-year-old woman recently diagnosed with thyroid cancer, who had been 
treated for stage IIA breast cancer 8 years ago. After radical right thyroidectomy and left sub-
total thyroidectomy, her pathological report showed papillary thyroid carcinoma, right thyroid, 
with concomitant metastatic breast carcinoma. This is the first case of which we are aware in-
volving coexisting thyroid cancer and metastatic breast cancer in the ipsilateral lobe. Moreover, 
the circumstances of this case show a very unique clinical course compared with previous 
studies. Given the unusual circumstances of our case, we further discuss the relationship be-
tween thyroid cancer and breast cancer. 
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中文摘要 
  甲狀腺是一個不尋常的癌症轉移位置。甲狀腺被癌症轉移通常發生在已有他處轉移
的情況下，而且一般預後不佳。我們舉出一位 49 歲的女性，曾在八年前罹患第二期乳癌
並接受過手術與化學治療。她後來被診斷出罹患甲狀腺癌。經過右側甲狀腺根除術與左
側次全甲狀腺切除術。病理報告顯示，右側乳突性甲狀腺癌，同時伴隨乳癌轉移至右側
甲狀腺。這是第一例甲狀腺癌與轉移性乳癌並存在同一側甲狀腺的病例。而且與以前的
文獻相較，它表現出非常獨特的臨床病程。我們也針對甲狀腺癌和乳癌的的關係進行了
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 討論。 
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INTRODUCTION 
Although rich in vasculature, the thyroid gland is a 
rare site of metastatic diseases, accounting for only 
2–3% of all malignant tumors of the thyroid [1]. Tu-
mors of the breast, bronchi, gastrointestinal system 
and kidneys are the most common sites of origin [1]. 
Metastasis to the thyroid gland usually occurs with 
concomitant metastases elsewhere [2], and often im-
plies poor prognosis for patients who usually die 
shortly after the appearance of thyroid metastasis [2,3]. 
Here we reported a case of thyroid cancer with con-
comitant breast cancer metastasis within the same lobe. 
After satisfactory treatment, the patient had survived 
disease-free, with no sign of either cancer for years.  
 
CASE REPORT  
A 49-year-old woman was diagnosed with and 
treated for breast cancer 8 years ago. She had under-
gone modified radical mastectomy to address left side 
breast cancer. Pathological report showed infiltrating 
duct carcinoma of the left breast, pT2N0M0, stage IIA, 
estrogen receptors (ER)-positive, progesterone recep-
tor (PR)-positive, Her-2/Neu-negative. Then she re-
ceived adjuvant chemotherapy with CMF (cyclo-
phosphamide, methotrexate and fluorouracil) regimen 
and tamoxifen. 
The patient had a past history of goiter and hypo-
thyroidism when undergoing Eltroxin therapy. In 2007, 
an enlarged right neck mass was noted. Sonography 
revealed a 5 x 4 x 3 cm nodule with cyst formation in 
the right lobe, and two small nodules with calcifica-
tions in the left lobe. Fine needle aspiration showed 
atypical cells. Thyroid cancer was suspected, and rad-
ical right thyroidectomy with lymph node dissection 
and left subtotal thyroidectomy were undertaken.  
The histological sections showed coexisting pa-
pillary thyroid cancer tissue and some mucinous met-
astatic neoplasm (Figure 1A). Papillary tumor was 
mixed with follicular composition (Figure 1B), and its 
cytological features (papillary architecture, nuclear 
pseudo-inclusions, nuclear grooves, lack of nucleoli) 
are well-recognized (Figure 1C). One piece of histol-
ogy-distinct tissue was identified among the papillary 
neoplastic area (Figure 2A) with prominent nucleoli 
(Figure 2B), which is impressed as a metastatic neo-
plasm. The TTF-1 stain showed positive in normal and 
neoplastic thyroid cells, but negative in the metastatic 
cells (Figure 3A). The metastatic tumors were positive 
for ER stain (Figure 3B) as well as the PR stain (Fig-
ure 3C). So the final pathological diagnosis was pa-
pillary thyroid carcinoma (pT3N0M0), right thyroid, 
with concomitant metastatic breast carcinoma, which 
most likely originated from the previous breast cancer 
diagnosed 8 years ago. 
Imaging survey showed no evidence of metastasis 
elsewhere on the patient. She then received one course 
of Iodine-131 therapy. Leuprorelin acetate (Leuplin) 
was then prescribed for one year, then therapy was 
shifted to the aromatase inhibitor after menopause. 
She then received regular follow-up and examination 
in our hospital and is currently free of both cancers. 
 
DISCUSSION 
Thyroid is an unusual site of cancer metastasis. In 
an autopsy study, breast and lung carcinoma are the 
two most frequently observed primary sites metasta-
sizing to thyroid [4]. However, in the clinical survey  
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Figure 1. (A) Within the thyroid specimen, it shows 
coexisting papillary thyroid cancer tissues 
(right side) and mucinous metastatic neo-
plasm (left side) (100X). (B) Papillary thy-
roid cancer tissue is mixed with follicular 
composition (B), which is follicular vari-
ant (200X). (C) The cytological features of 
papillary thyroid cancer: nuclear pseu-
do-inclusions (B), nuclear grooves (➯), 
lack of nucleoli (800X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (A) One piece of histology-distinct tissue (labeled “B”) is identified among the papillary neoplastic area 
(100X). (B) Cells within this “B” area have nucleoli (B), which are lacking in thyroid cancer cells (➯) 
(400X) 
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Figure 3. (A) The TTF-1 stain shows positive in nor-
mal and neoplastic thyroid cells, but nega-
tive in metastatic cancer cells (with nucleoli) 
(400X). (B) The estrogen-receptor stain 
shows positive only in metastatic cancer 
cells (400X). (C) The progesterone-receptor 
stain shows positive only in metastatic 
cancer cells (800X) 
 
 
 
 
of thyroid metastasis, kidney was the most common 
primary tumor site (33%), followed by lung (16%), 
breast (16%), esophagus (9%), and uterus (7%) [5]. 
Metastasis to the thyroid gland usually occurs with 
concomitant metastases at other organs [2,6], and of-
ten implies poor prognosis of patients [2] with median 
survival time around 10 months [3]. Thyroid metasta-
sis usually occurs late after diagnosis of primary tu-
mor, with mean duration of 106 months for renal cell 
carcinoma, 131 months for breast cancer, and 132 
months for uterine cancer [5]. In our case, it took 8 
years after diagnosis of primary breast cancer to detect 
metastasis to the thyroid gland. However, there was no 
concomitant metastasis into other organs. Furthermore, 
the patient’s chances of achieving long-term survival 
and remaining disease-free could improve after thera-
py. 
Patients with breasts cancer may have an increased 
risk for thyroid cancer. In 1987, an epidemiological 
analysis by McTiernan revealed women with a history 
of breast cancer were almost 3 times more likely to 
develop thyroid cancer [7]. A retrospective study of 
2786 newly diagnosed breast cancer patients in Japan 
also demonstrated a significantly increased risk of 
ovarian cancer, thyroid cancer and non-Hodgkin's 
lymphoma compared to the general population [8]. In 
a recent study, sonographic screening for thyroid can-
cer in females undergoing concomitant breast sonog-
raphy showed a significantly higher incidence of thy-
roid cancer in the breast cancer group than those 
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 without such cancer [9]. Sonographic screening of 
breast cancer patients in Korea also showed a high 
incidence (2.5 %) of thyroid cancer [10]. 
On the other hand, in a study done by the M.D. 
Anderson Cancer Center, an increased incidence of 
subsequent breast carcinoma was found in young adult 
women (40-49 y/o) who had a history of thyroid can-
cer [11]. According to the data from the Surveillance, 
Epidemiology and End Results (SEER), patients 
younger than 40 years of age at the time of diagnosis 
of thyroid cancer had a 39% increased risk of a second 
cancer of the breast, prostate, and kidney [12]. Anoth-
er SEER analysis of 1,333,115 persons also demon-
strated premenopausal women with thyroid carcinoma 
have a significantly increased risk of subsequent 
breast carcinoma [13]. So patients with thyroid cancer 
may also have elevated chances of developing breast 
cancer. 
There are also studies regarding the correlation 
between breast cancer and non-malignant thyroid dis-
ease. In 1996, a prospective study by Giani et al. re-
vealed that the overall prevalence of thyroid disease 
(including nontoxic goiter and Hashimoto's thyroiditis) 
in breast cancer patients was higher than in the control 
group [14]. The prevalence of the presence of thyrop-
eroxidase antibody, an indicator of Hashimoto's thy-
roiditis, is higher in breast cancer patients than in con-
trols (23.5% vs. 8%; P < 0.005) [15]. Previous studies 
have also shown that preexisting thyroid disease (i.e., 
multinodular goiter and thyroid nodules) may provide 
a nidus for metastases to the thyroid gland [4]. Our 
patient had a history of goiter with hypothyroidism, 
which may facilitate the metastasis of her breast can-
cer to the thyroid gland. 
The presence of ERs in papillary thyroid carcino-
ma has been demonstrated by immunohistochemistry, 
indicating that estrogen may affect the proliferation of 
ER-positive papillary thyroid carcinoma [16]. Higher 
levels of ERs were also found in neoplastic than in 
normal thyroid tissues [17]. 17ß-estradiol, a potent 
mitogen for benign and malignant thyroid tumor cells, 
could exert a growth-promoting effect by activating 
mitogen-activated protein kinase pathway [18]. In ad-
dition, a rare genetic syndrome, Cowden’s disease, 
had increased the risk of both breast and follicular 
thyroid cancers [19]. These studies provide possible 
explanations of the mechanism of sequential occur-
rence of these two cancers. 
The patient here presented a case of occult metas-
tases, which by definition are not detected on routine 
imaging examination. They are usually detected inci-
dentally on pathology tissues obtained for other pur-
poses [20]. For occult metastases, it takes a long time 
before the spreading cancer becomes clinically evident, 
and therefore shows better prognosis than frank me-
tastases. For this patient, she received therapy imme-
diately after diagnosis, which could explain her good 
prognosis in comparison with previous reports.  
In conclusion, we presented a rare case with con-
comitant primary thyroid cancer and metastatic breast 
cancer within the same lobe of the thyroid. Unlike 
previous reports, our patient did not have disseminat-
ed disease and enjoyed long-term disease-free survival 
after therapy. Coexisting breast cancer and thyroid 
cancer, although rare, should be viewed as a diagnos-
tic option requiring timely treatment in clinical prac-
tice when appropriate.  
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